Rapt Therapeutics (NASDAQ:RAPT), a clinical-stage biopharmaceutical company based in California, is making headlines with its recent acquisition news. Specializing in the development of innovative therapies for inflammatory and immunologic diseases, RAPT has been a key player in this competitive field, alongside major competitors like GSK plc, a British drugmaker. Despite a recent downgrade from Guggenheim, from a Buy to a Neutral rating, RAPT's stock saw a significant surge, climbing 64% to reach $57. This increase came in the wake of GSK's announcement to acquire RAPT for $58.00 per share, valuing the deal at approximately $2.2 billion.

The acquisition deal, involving an upfront investment of $1.9 billion net of cash acquired, gives GSK access to RAPT's late-stage food allergy treatment, ozureprubart, a long-acting anti-IgE monoclonal antibody. Currently in phase 2b clinical development, ozureprubart aims to offer prophylactic protection against food allergens. This innovative drug targets IgE, a validated target in severe food allergies, promising a more convenient option for patients compared to current treatments that require frequent injections.

Meanwhile, Halper Sadeh LLC, a law firm specializing in investor rights, is investigating the fairness of the sale of RAPT to GSK. This investigation seeks to determine if the sale is in the best interest of RAPT shareholders and if the board of directors has fulfilled its duties. The stock has reached a new 52-week high of $57.61, with a market capitalization of approximately $951.3 million.